Role of the N-terminal region in G protein-coupled receptor functions: Negative modulation revealed by 5-HT2B receptor polymorphisms

Molecular Pharmacology

Volumn 85, Issue 1, 2014, Pages 127-138

  Belmer, Arnauld ^a   Doly, Stephane ^a   Setola, Vincent ^a   Banas, Sophie M ^a   Moutkine, Imane ^a   Boutourlinsky, Katia ^a   Kenakin, Terry ^b   Maroteaux, Luc ^a  

^a INSTITUT DU FER À MOULIN   (France)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; INOSITOL PHOSPHATE; SEROTONIN 2B RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; BIOACCUMULATION; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN COS7; CONTROLLED STUDY; DNA MODIFICATION; DRUG ABUSE; GENE; HUMAN; IN VITRO STUDY; MODULATION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVERTANT; SEROTONIN 2B RECEPTOR GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

EID: 84890707732     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.089086     Document Type: Article

References (30)

1. Achour L, Kamal M, Jockers R, and Marullo S (2011) Using quantitative BRET to assess G protein-coupled receptor homo-and heterodimerization. Methods Mol Biol 756:183-200.
2. Andersson H, D'Antona AM, Kendall DA, Von Heijne G, and Chin CN (2003) Membrane assembly of the cannabinoid receptor 1: Impact of a long N-terminal tail. Mol Pharmacol 64:570-577.
3. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
4. Colas J-F, Choi D-S, Launay J-M, and Maroteaux L (1997) Evolutionary conservation of the 5-HT2B receptors. Ann N Y Acad Sci 812:149-153.
5. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, and Rauly-Lestienne I (2008) Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol 594:32-38.
6. Deraet M, Manivet P, Janoshazi A, Callebert J, Guenther S, Drouet L, Launay JM, and Maroteaux L (2005) The natural mutation encoding a C terminus-truncated 5-hydroxytryptamine 2B receptor is a gain of proliferative functions. Mol Pharmacol 67:983-991.
7. Doly S, Bertran-Gonzalez J, Callebert J, Bruneau A, Banas SM, Belmer A, Boutourlinsky K, Hervé D, Launay JM, and Maroteaux L (2009) Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice. PLoS ONE 4: E7952.
8. Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, and Maroteaux L (2008) Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamineinduced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci 28: 2933-2940.
9. Dunham JH, Meyer RC, Garcia EL, and Hall RA (2009) GPR37 surface expression enhancement via N-terminal truncation or protein-protein interactions. Biochemistry 48:10286-10297.
10. Ehlert FJ (2005) Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315:740-754.
11. Ersoy BA, Pardo L, Zhang S, Thompson DA, Millhauser G, Govaerts C, and Vaisse C (2012) Mechanism of N-terminal modulation of activity at the melanocortin-4 receptor GPCR. Nat Chem Biol 8:725-730.
12. Green S, Issemann I, and Sheer E (1988) A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res 16: 369.
13. Green SA, Turki J, Innis M, and Liggett SB (1994) Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33:9414-9419.
14. Hague C, Chen Z, Pupo AS, Schulte NA, Toews ML, and Minneman KP (2004) The N terminus of the human alpha1D-adrenergic receptor prevents cell surface expression. J Pharmacol Exp Ther 309:388-397.
15. Huang J, Chen S, Zhang JJ, and Huang X-Y (2013) Crystal structure of oligomeric b1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat Struct Mol Biol 20:419-425.
16. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, and Novick S (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3:193-203.
17. Levin MC, Marullo S, Muntaner O, Andersson B, and Magnusson Y (2002) The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 277:30429-30435.
18. Lin Z, Walther D, Yu X-Y, Drgon T, and Uhl GR (2004) The human serotonin receptor 2B: Coding region polymorphisms and association with vulnerability to illegal drug abuse. Pharmacogenetics 14:805-811.
19. Mancia F, Assur Z, Herman AG, Siegel R, and Hendrickson WA (2008) Ligand sensitivity in dimeric associations of the serotonin 5HT2c receptor. EMBO Rep 9: 363-369.
20. Manivet P, Schneider B, Smith JC, Choi DS, Maroteaux L, Kellermann O, and Launay JM (2002) The serotonin binding site of human and murine 5-HT2B receptors: Molecular modeling and site-directed mutagenesis. J Biol Chem 277: 17170-17178.
21. McRobb FM, Capuano B, Crosby IT, Chalmers DK, and Yuriev E (2010) Homology modeling and docking evaluation of aminergic G protein-coupled receptors. J Chem Inf Model 50:626-637.
22. Ramachandran R and Hollenberg MD (2008) Proteinases and signalling: Pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 153 (Suppl 1):S263-S282.
23. Rana S and Baranski TJ (2010) Third extracellular loop (EC3)-N terminus interaction is important for seven-transmembrane domain receptor function: Implications for an activation microswitch region. J Biol Chem 285:31472-31483.
24. Setola V, Dukat M, Glennon RA, and Roth BL (2005) Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor. Mol Pharmacol 68:20-33.
25. Smith NJ, Bennett KA, and Milligan G (2011) When simple agonism is not enough: Emerging modalities of GPCR ligands. Mol Cell Endocrinol 331:241-247.
26. Srinivasan S, Lubrano-Berthelier C, Govaerts C, Picard F, Santiago P, Conklin BR, and Vaisse C (2004) Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J Clin Invest 114:1158-1164.
27. Strasser A, Wittmann HJ, and Seifert R (2008) Ligand-specific contribution of the N terminus and E2-loop to pharmacological properties of the histamine H1-receptor. J Pharmacol Exp Ther 326:783-791.
28. Vassart G, Pardo L, and Costagliola S (2004) A molecular dissection of the glycoprotein hormone receptors. Trends Biochem Sci 29:119-126.
29. Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, McCorvy JD, Jiang Y, Chu M, and Siu FY et al. (2013) Structural features for functional selectivity at serotonin receptors. Science 340:615-619.
30. Wittmann H-J, Seifert R, and Strasser A (2011) Influence of the N-terminus and the E2-loop onto the binding kinetics of the antagonist mepyramine and the partial agonist phenoprodifen to H(1)R. Biochem Pharmacol 82:1910-1918.